concanavalin-a and narciclasine

concanavalin-a has been researched along with narciclasine* in 1 studies

Other Studies

1 other study(ies) available for concanavalin-a and narciclasine

ArticleYear
Narciclasine ameliorated T cell mediated acute liver injury through activating AMPK pathway.
    Cellular immunology, 2022, Volume: 382

    Hepatitis is closely related to cirrhosis and liver cancer, and it is vital that we develop new drugs and identify new drug targets. Traditional Chinese medicine has demonstrated excellent curative effects on liver diseases. The ingredients from Chinese herbals are important source for drug development in the treatment of hepatitis. Here, we found that narciclasine (NCS), a major component extracted from narcissus bulbs, showed hepatoprotective effect against concanavalin A (Con A) induced hepatitis. NCS treatment significantly reduced hepatocyte death, hepatic inflammatory cells infiltration, and serum cytokine levels in Con A challenged mice. We further observed that NCS directly inhibited Con A induced splenocytes proliferation and cytokine production in vitro. RNA-seq results showed that genes related to immune response were upregulated in Con A treated CD4

    Topics: AMP-Activated Protein Kinases; Animals; Concanavalin A; Cytokines; Liver; Mice; Mice, Inbred C57BL; T-Lymphocytes

2022